Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Gout Clinical Trial

— EXCEL  

Official title:

A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00175019
• Other study ID #: C02-021
• Secondary ID: U1111-1113-9814
• Status: Completed
• Phase: Phase 3
• First received: September 12, 2005
• Last updated: July 22, 2010
• Start date: July 2003
• Est. completion date: February 2007

Study information

• Verified date: July 2010
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.

Description:

Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 mg/dL), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often insufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or partially of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate levels into a subsaturating range (usually <6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for the management of hyperuricemia in patients with gout.

This study was originally designed and initiated having all subjects initially assigned to 80 mg febuxostat provided as an 80 mg tablet, to be administered orally. Subjects could be titrated to 120 mg, provided as one 40 and 80 mg tablet, between Months 2 and 6, if their serum uric acid rose > 6.0 mg/dL; the dose could be down-titrated to 80 mg if the serum uric acid decreased to < 3.0 mg/dL.

The protocol was amended to add a comparator arm, and to have subjects randomized to 80 or 120 mg febuxostat or allopurinol (100 or 300 mg, dependent on renal function). The information below reflects the treatments following the implementation of the revised protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1086
• Est. completion date: February 2007
• Est. primary completion date: February 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).

• Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).

• Has participated in a clinical study in which febuxostat was administered.

• Is completing Phase 3 Studies C02-009 or C02-010.

• Must not have experienced any serious study drug-related adverse events in the previous study.

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study

Exclusion Criteria:

• Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.

• Is intolerant of allopurinol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gout

Intervention

Drug:
• Febuxostat
Febuxostat 80 mg, tablets, orally, once daily.
• Febuxostat
Febuxostat 120 mg, tablets, orally, once daily.
• Allopurinol
Allopurinol 100 mg or 300 mg, tablets, orally, once daily.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

References & Publications (1)

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.	Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 1 visit was summarized.	Month 1	No
Primary	Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.	Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized.	Month 12	No
Primary	Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.	Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized.	Month 24	No
Primary	Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.	Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized.	Month 36	No
Primary	Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.	The percentage of subjects whose serum urate was <6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.	Last Visit on treatment (up to 40 months).	No
Secondary	Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.	The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.	Last Visit on treatment (up to 40 months).	No
Secondary	Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.	The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.	Month 12	No
Secondary	Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.	The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.	Month 24	No
Secondary	Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.	The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.	Month 36	No
Secondary	Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.	The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.	Final Visit (up to 40 months).	No
Secondary	Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.	The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.	Final Visit (up to 40 months).	No
Secondary	Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.	The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.	Month 12	No
Secondary	Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.	The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.	After Month 12 to Final Visit	No

External Links

•   FDA Safety Alerts and Recalls
•   Uloric Package Insert